TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1193075

Group type: EXPERIMENTAL
Intervention: 6 wk high intensity, low repetition strength conditioning programme
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Inactivity periods of 1, 4, 6, and 8 wk
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1 wk of detraining
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Detraining of 4, 6, and 8 wk
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Inactivity periods of 6 and 8 wk
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 31607172

Group type: EXPERIMENTAL
Intervention: Serious gaming based on transferring information, priming and evaluative conditioning for half an hour
Number of subjects: 81

Group type: COMPARATOR
Intervention: Non-health‐related computer games
Number of subjects: 81
Study: 31484710

Group type: COMPARATOR
Intervention: ocrelizumab (600 mg)
Number of subjects: 0
Study: 28118402

Group type: EXPERIMENTAL
Intervention: Direct Renin Inhibition (DRI; aliskiren 300 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Angiotensin Converting Enzyme Inhibition (ACEi; ramipril 10 mg/day)
Number of subjects: 15
Study: 25952550

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) training program (12-week, 14-hour)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 17
Study: 23557331

Group type: EXPERIMENTAL
Intervention: Text-message reminders
Number of subjects: 6450

Group type: COMPARATOR
Intervention: Telephone reminders
Number of subjects: 6450
Study: 21208354

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 1250
Study: 19141573

Group type: EXPERIMENTAL
Intervention: Activity Participation Questionnaire (APaQ)
Number of subjects: 1043
Study: 17339133

Group type: EXPERIMENTAL
Intervention: Contrast temperature water therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Active recovery
Number of subjects: 20
Study: 15274095

Group type: EXPERIMENTAL
Intervention: BDP-CFC aerosol (>or= 500 mcg/day) via nasal inhalation
Number of subjects: 75

Group type: COMPARATOR
Intervention: 200 mcg/day of aqueous intranasal beclomethasone plus oral inhalation of BDP-CFC (>or= 500 mcg/day)
Number of subjects: 75
Study: 11373466

Group type: EXPERIMENTAL
Intervention: Afelimomab
Number of subjects: 446

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 446

Group type: COMPARATOR
Intervention: Nonrandomized patients
Number of subjects: 446
Study: 9127135

Group type: EXPERIMENTAL
Intervention: Granisetron alone
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Methylprednisolone plus granisetron
Number of subjects: 85

Group type: COMPARATOR
Intervention: Metoclopramide alone
Number of subjects: 85
Study: 8088931

Group type: EXPERIMENTAL
Intervention: doxofylline 800 mg b.i.d.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: theophylline slow-release 400 mg b.i.d.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: bamifylline 1200 mg b.i.d.
Number of subjects: 48
Study: 3318434

Group type: EXPERIMENTAL
Intervention: 1,000 mg of nabumetone as a single bedtime dose
Number of subjects: 332

Group type: COMPARATOR
Intervention: 900 mg of aspirin in four divided doses
Number of subjects: 332
Study: 29470685

Group type: EXPERIMENTAL
Intervention: Halogen light stimulation
Number of subjects: 598

Group type: COMPARATOR
Intervention: No light stimulation
Number of subjects: 598
Study: 26658441

Group type: EXPERIMENTAL
Intervention: Radiosurgery (22 Gy margin dose, follow-up 86 months)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Radiosurgery
Number of subjects: 509
Study: 24631386

Group type: EXPERIMENTAL
Intervention: Yacon flour (0.14 g of fructooligosaccharides/kg of body weight daily) for 18 weeks
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Yacon flour
Number of subjects: 117

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 117
Study: 23035743

Group type: EXPERIMENTAL
Intervention: Green tea catechin (GTC) supplementation (630.9 mg GTC daily, n=26)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (n=26)
Number of subjects: 52
Study: 20836779

Group type: EXPERIMENTAL
Intervention: Videotaped practice and feedback
Number of subjects: 34
Study: 18039889

Group type: EXPERIMENTAL
Intervention: Paging system for memory and planning problems after brain injury
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Paging system for TBI participants
Number of subjects: 36

Group type: COMPARATOR
Intervention: CVA participants
Number of subjects: 36
Study: 15962683

Group type: EXPERIMENTAL
Intervention: Waiver of consent for retrospective chart reviews
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Waiver of consent for prospective observational studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized clinical trials
Number of subjects: 0
Study: 12884343

Group type: EXPERIMENTAL
Intervention: Total laryngectomy with pharyngeal neurectomy (PN)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Total laryngectomy without pharyngeal neurectomy (C)
Number of subjects: 45
Study: 12923650

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (500 I.U. D‐alpha‐tocopherol)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 13
Study: 9477148

Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 23
Study: 7533461

Group type: EXPERIMENTAL
Intervention: Finasteride (10 mg/d)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 2529375

Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg orally
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21677

Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 97

Group type: COMPARATOR
Intervention: Althesin
Number of subjects: 97
Study: 31099141

Group type: EXPERIMENTAL
Intervention: Methamphetamine (20 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 28186540

Group type: EXPERIMENTAL
Intervention: Low-dose continuous erythropoiesis receptor activator (CERA; monthly dose 30–75 µg)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Low-dose continuous erythropoiesis receptor activator (CERA)
Number of subjects: 235
Study: 24859614

Group type: EXPERIMENTAL
Intervention: Oropharyngeal exercises (Group 1)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 27
Study: 23247045

Group type: EXPERIMENTAL
Intervention: Combination therapy with steroids plus pentostatin, mycophenolate mofetil, etanercept, or denileukin diftitox
Number of subjects: 0
Study: 21839033

Group type: EXPERIMENTAL
Intervention: Topical cosmetic product containing various active ingredients of botanical origin
Number of subjects: 0
Study: 19797281

Group type: EXPERIMENTAL
Intervention: Intensive care with cooling to 33.5 degrees C for 72 hours
Number of subjects: 325

Group type: COMPARATOR
Intervention: Intensive care alone
Number of subjects: 325
Study: 16691086

Group type: EXPERIMENTAL
Intervention: Genuine acupuncture needle
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham needle
Number of subjects: 41
Study: 14631163

Group type: EXPERIMENTAL
Intervention: 24% sucrose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sterile water (placebo)
Number of subjects: 0
Study: 11780330

Group type: EXPERIMENTAL
Intervention: Captopril (6.25 mg to 25 mg t.i.d.)
Number of subjects: 822

Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 822
Study: 9032180

Group type: EXPERIMENTAL
Intervention: Sputum from asthmatic subjects
Number of subjects: 0
Study: 8515495

Group type: EXPERIMENTAL
Intervention: Immediate treatment with high-dose chemotherapy (cyclophosphamide 1875 mg/m2, cisplatin 55 mg/m2, carmustine 600 mg/m2) followed by autologous bone marrow reinfusion.
Number of subjects: 39

Group type: COMPARATOR
Intervention: Observation until relapse followed by the same high-dose chemotherapy and autologous bone marrow reinfusion.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both treatment arms (immediate treatment and observation)
Number of subjects: 39
Study: 31453883

Group type: EXPERIMENTAL
Intervention: aTDCS (1.5 mA for 18 min) with eccentric exercise
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham stimulation with eccentric exercise
Number of subjects: 26
Study: 29224059

Group type: EXPERIMENTAL
Intervention: Knotless suture button device
Number of subjects: 54

Group type: COMPARATOR
Intervention: Syndesmotic screw fixation
Number of subjects: 54
Study: 27579536

Group type: EXPERIMENTAL
Intervention: Tivantinib (MET inhibitor)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Baseline circulating MET
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Baseline circulating HGF
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: AFP
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: VEGF
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 102
Study: 24990455

Group type: EXPERIMENTAL
Intervention: Educational intervention (lecture, posters, pocket protocols) at hospital 1
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (hospital 2, merely informed of the audit)
Number of subjects: 109
Study: 22378334

Group type: EXPERIMENTAL
Intervention: Breastfeeding (BF)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Formula feeding (FF)
Number of subjects: 338
Study: 20698216

Group type: EXPERIMENTAL
Intervention: roxatidine acetate 75 mg twice daily (n = 16)
Number of subjects: 33

Group type: COMPARATOR
Intervention: omeprazole 20 mg once daily (n = 17)
Number of subjects: 33
Study: 18209165

Group type: EXPERIMENTAL
Intervention: Dapsone
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Dapsone (after switching from placebo)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 19
Study: 15880021

Group type: EXPERIMENTAL
Intervention: Everolimus with reduced-exposure cyclosporine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Everolimus dose reduction
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Low dose furosemide
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Povidine-iodine instillations
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 3
Study: 12682838

Group type: EXPERIMENTAL
Intervention: Vitamin C (VC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 16
Study: 11219598

Group type: EXPERIMENTAL
Intervention: Excimer laser angioplasty
Number of subjects: 308

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 308
Study: 9062051

Group type: EXPERIMENTAL
Intervention: Exercise (running 9.6 km in an hour)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 8
Study: 2004922

Group type: EXPERIMENTAL
Intervention: Milking protocol
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Stripping protocol
Number of subjects: 200

Group type: COMPARATOR
Intervention: No manipulation (first 8 hours)
Number of subjects: 200
Study: 6734422

Group type: COMPARATOR
Intervention: Lorazepam 0.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lorazepam 1.0 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lorazepam 2.0 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam 5 mg
Number of subjects: 0
Study: 30584136

Group type: EXPERIMENTAL
Intervention: Intervention group (caregivers)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 226
Study: 30314463

Group type: EXPERIMENTAL
Intervention: Heteroscedastic partially nested mixed-effects model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fully clustered mixed effects models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partially nested mixed-effects models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All models assessed
Number of subjects: 0
Study: 26520208

Group type: EXPERIMENTAL
Intervention: Relaxation techniques
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (information-based training courses)
Number of subjects: 59
Study: 24931393

Group type: EXPERIMENTAL
Intervention: New-onset atrial fibrillation (Group 1)
Number of subjects: 2392
Study: 21655910

Group type: EXPERIMENTAL
Intervention: Visible light-cured resin (VLCR) denture base material
Number of subjects: 90

Group type: COMPARATOR
Intervention: Polymethylmethacrylate (PMMA) denture acrylic
Number of subjects: 90
Study: 20181388

Group type: EXPERIMENTAL
Intervention: Lithium disilicate glass-ceramic restorations
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Leucite reinforced glass-ceramic restorations
Number of subjects: 32

Group type: COMPARATOR
Intervention: Different preparation designs (non-retentive, occlusal preparation with chamfer or straight-beveled finishing line)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Design of the finishing line
Number of subjects: 32
Study: 17682090

Group type: EXPERIMENTAL
Intervention: Genistein (54 mg/d)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study: 15737442

Group type: EXPERIMENTAL
Intervention: Total lumbar disc replacement
Number of subjects: 29
Study: 12087568

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa administered IV once weekly
Number of subjects: 507

Group type: COMPARATOR
Intervention: Epoetin administered IV three times weekly
Number of subjects: 507
Study: 9468804

Group type: EXPERIMENTAL
Intervention: Aerobic exercise during learning and recall
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rest during learning and recall
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changed state conditions (exercise to rest or rest to exercise)
Number of subjects: 0
Study: 8585775

Group type: EXPERIMENTAL
Intervention: 160 mg trimethoprim and 800 mg sulfamethoxazole twice a day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 250 mg ciprofloxacin twice a day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 1974143

Group type: EXPERIMENTAL
Intervention: Propranolol LA (160 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Metoprolol CR (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor blockers (Propranolol LA, Atenolol, Metoprolol CR)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 875101

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Massive steroids
Number of subjects: 58

Group type: COMPARATOR
Intervention: Increased fluid intake
Number of subjects: 58

Group type: COMPARATOR
Intervention: Increased glucose intake
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control
Number of subjects: 58
Study: 30470804

Group type: COMPARATOR
Intervention: Continuous energy restriction (CER) at 4200 kJ/day for women and 5040 kJ/day for men
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Week-on-week-off energy restriction (alternating between energy restriction and habitual diet)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: 5:2 energy restriction (2100 kJ/day for women and 2520 kJ/day for men on modified fast days)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 332
Study: 30361080

Group type: EXPERIMENTAL
Intervention: Imipramine (25 mg once nightly for the first 2 weeks, then 50 mg thereafter)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 107
Study: 26852237

Group type: EXPERIMENTAL
Intervention: SMS intervention
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Peer navigation intervention
Number of subjects: 750

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 750
Study: 23925496

Group type: EXPERIMENTAL
Intervention: Small-group-discussion (SGD) programme
Number of subjects: 2169

Group type: COMPARATOR
Intervention: Practice-while-watching (PWW) programme
Number of subjects: 2169
Study: 22965294

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) - Sensor On
Number of subjects: 153

Group type: COMPARATOR
Intervention: Continuous Glucose Monitoring (CGM) - Sensor Off
Number of subjects: 153
Study: 20124412

Group type: COMPARATOR
Intervention: 75 mg of prednisolone (single dose)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 30 mg of prednisolone daily for 15 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 17535462

Group type: EXPERIMENTAL
Intervention: Haptic‐haptic (T‐T) discrimination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haptic‐visual (T‐V) discrimination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual‐visual (V‐V) discrimination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual‐haptic (V‐T) discrimination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined analysis of inter‐modal (V‐T, T‐V) and intra‐modal (V‐V, T‐T) conditions
Number of subjects: 0
Study: 16003198

Group type: EXPERIMENTAL
Intervention: Bioabsorbable polylevolactic acid screw
Number of subjects: 38

Group type: COMPARATOR
Intervention: Metallic screw
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both screws
Number of subjects: 38
Study: 12452207

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg once daily
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study: 10080158

Group type: EXPERIMENTAL
Intervention: IFN‐alpha (6 million units once a day for one month and thrice weekly for five months)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IFN‐beta (6 million units once a day daily for two months)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IFN‐beta (3 million units twice a day for two months)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 7555487

Group type: EXPERIMENTAL
Intervention: Atropine (1.0 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo followed by Atropine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo only
Number of subjects: 8
Study: 1970284

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid enemas (4 gm daily for the first seven days of each month)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral sulfasalazine (2 gm daily as oral tablets)
Number of subjects: 60
Study: 6164465

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation (45 Gy) + Bleomycin (15 mg doses, total 180 mg)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation (45 Gy) + Placebo
Number of subjects: 118

Group type: COMPARATOR
Intervention: Conventional care (no radiotherapy or chemotherapy)
Number of subjects: 118
Study: 31500661

Group type: EXPERIMENTAL
Intervention: Referral networks strengthened with health information technology and peer support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care for referrals
Number of subjects: 0
Study: 29295592

Group type: EXPERIMENTAL
Intervention: Electronic voltammetric tongue
Number of subjects: 83

Group type: COMPARATOR
Intervention: Routine analytical methods
Number of subjects: 83
Study: 25897676

Group type: COMPARATOR
Intervention: selumetinib 75 mg p.o. bid
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: selumetinib 50 mg p.o. bid plus temsirolimus 20 mg i.v. weekly
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: selumetinib plus temsirolimus
Number of subjects: 71
Study: 23400744

Group type: EXPERIMENTAL
Intervention: Treprostinil 250 µM
Number of subjects: 20

Group type: COMPARATOR
Intervention: NaCl 0.9%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treprostinil 2.5 µM
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treprostinil 25 µM
Number of subjects: 20
Study: 21078303

Group type: EXPERIMENTAL
Intervention: Perimenopausal hormone therapy (HT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Never users of hormone therapy (HT)
Number of subjects: 34
Study: 19961458

Group type: EXPERIMENTAL
Intervention: ProTaper Universal rotary system
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nitiflex files (control)
Number of subjects: 20
Study: 17278974

Group type: EXPERIMENTAL
Intervention: Alagebrium (ALT-711; 210 mg twice a day for 8 weeks)
Number of subjects: 13
Study: 15126734

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanate (A/C)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both treatments (Clarithromycin and A/C)
Number of subjects: 22
Study: 10570555

Group type: EXPERIMENTAL
Intervention: Topical terbinafine 1% cream twice daily for 1 week, followed by placebo cream for 5 weeks
Number of subjects: 217

Group type: COMPARATOR
Intervention: Topical clotrimazole 1% cream twice daily for 4 weeks
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Topical terbinafine
Number of subjects: 217

Group type: COMPARATOR
Intervention: Topical clotrimazole
Number of subjects: 217
Study: 8728447

Group type: EXPERIMENTAL
Intervention: Women aged 26-30 years
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Women aged > 30 years
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Women with Quetelet's index > 25-30
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Women with Quetelet's index > 30
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Parous women (1 birth)
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Parous women (2 or more births)
Number of subjects: 756
Study: 2008069

Group type: EXPERIMENTAL
Intervention: Milieu Teaching
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Communication Training Program
Number of subjects: 40
Study: 6981176

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) therapy for treatment: 20 mg of TMP and 100 mg of SMZ per kg of body weight per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) prophylactic therapy: 5.0 mg of TMP and 25 mg of SMZ per kg of body weight per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unstructured delivery of prophylactic TMP-SMZ
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pentamidine isethionate
Number of subjects: 0